Annales d'Endocrinologie 2013-02-01

Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.

Salha Fendri, Pelin Karaca, Evelyne Tiev, Michael Buchfelder, Jean-Daniel Lalau

文献索引：Ann. Endocrinol. (Paris.) 74(1) , 49-52, (2013)

全文：HTML全文

摘要

We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and radiotherapy treatment to restore IGF-1 levels. The combination treatment was well tolerated and produced a dramatic improvement in the patient's condition (reduction in visual field defects, relief of headache and excessive perspiration), normalization of IGF-I levels and a considerable decrease in tumor size, enabling a dramatic decrease in lanreotide dosage and, ultimately, its withdrawal.Copyright © 2012 Elsevier Masson SAS. All rights reserved.

相关化合物

  • 兰瑞肽乙酸盐

相关文献：

[Drug therapy for acromegaly].

2013-09-29

[Orv. Hetil. 154(39) , 1527-34, (2013)]

Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases.

2013-09-01

[Pituitary 16(3) , 354-62, (2013)]

Merkel cell carcinoma of the auricle: a treacherous skin tumor.

2012-01-01

[J. Cancer Res. Ther. 8(3) , 460-2, (2012)]

Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction.

2012-12-10

[J. Clin. Oncol. 30(35) , 4290-1, (2012)]

Carcinoid crisis induced by repeated abdominal examination.

2012-03-01

[Intern. Med. J. 42(3) , 342-4, (2012)]

更多文献...